ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P04578


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name ENV_HV1H2
Primary accession number P04578
Secondary accession number O09779
Integrated into Swiss-Prot on August 13, 1987
Sequence was last modified on July 15, 1999 (Sequence version 2)
Annotations were last modified on    October 14, 2008 (Entry version 75)
Name and origin of the protein
Protein name Envelope glycoprotein gp160 [Precursor]
Synonym Env polyprotein
Contains Surface protein
     (SU)
     (Glycoprotein 120)
     (gp120)
Transmembrane protein
     (TM)
     (Glycoprotein 41)
     (gp41)
Gene name
Name: env
From
Human immunodeficiency virus type 1 (isolate HXB2 group M subtype B) (HIV-1) [TaxID: 11706] 
Taxonomy Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae; Lentivirus; Primate lentivirus group.
Virus host Homo sapiens (Human) [TaxID: 9606]
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC RNA].
PubMed=3040055 [NCBI, ExPASy, EBI, Israel, Japan]
Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.-S., Gallo R.C., Wong-Staal F.;
"Complete nucleotide sequences of functional clones of the AIDS virus.";
AIDS Res. Hum. Retroviruses 3:57-69(1987).
[2]
SEQUENCE REVISION.
Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.-S., Gallo R.C., Wong-Staal F.;
Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
[3]
IMMUNOSUPPRESSIVE REGION.
PubMed=7986401 [NCBI, ExPASy, EBI, Israel, Japan]
Denner J., Norley S., Kurth R.;
"The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients.";
AIDS 8:1063-1072(1994).
[4]
PALMITOYLATION, AND MUTAGENESIS OF CYS-764 AND CYS-837.
PubMed=7568235 [NCBI, ExPASy, EBI, Israel, Japan]
Yang C., Spies C.P., Compans R.W.;
"The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated.";
Proc. Natl. Acad. Sci. U.S.A. 92:9871-9875(1995).
[5]
INTERACTION OF SURFACE PROTEIN GP120 WITH GALACTOSYL CERAMIDE AND SULFO-GALACTOSYL CERAMIDE.
PubMed=7494242 [NCBI, ExPASy, EBI, Israel, Japan]
Harouse J.M., Collman R.G., Gonzalez-Scarano F.;
"Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line.";
J. Virol. 69:7383-7390(1995).
[6]
DOMAIN YXXL MOTIF.
PubMed=10233963 [NCBI, ExPASy, EBI, Israel, Japan]
Deschambeault J., Lalonde J.P., Cervantes-Acosta G., Lodge R., Cohen E.A., Lemay G.;
"Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission.";
J. Virol. 73:5010-5017(1999).
[7]
REVIEW.
DOI=10.1034/j.1600-0463.2003.11107803.x; PubMed=12974773 [NCBI, ExPASy, EBI, Israel, Japan]
Geijtenbeek T.B., van Kooyk Y.;
"Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity.";
APMIS 111:698-714(2003).
[8]
INTERACTION OF SURFACE PROTEIN GP120 WITH HOST CD209/DC-SIGN AND CLEC4M/DC-SIGNR.
DOI=10.1128/JVI.77.2.1337-1346.2003; PubMed=12502850 [NCBI, ExPASy, EBI, Israel, Japan]
Lin G., Simmons G., Poehlmann S., Baribaud F., Ni H., Leslie G.J., Haggarty B.S., Bates P., Weissman D., Hoxie J.A., Doms R.W.;
"Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.";
J. Virol. 77:1337-1346(2003).
[9]
STOICHIOMETRY OF ENVELOPE GLYCOPROTEIN.
DOI=10.1128/JVI.79.19.12132-12147.2005; PubMed=16160141 [NCBI, ExPASy, EBI, Israel, Japan]
Yang X., Kurteva S., Ren X., Lee S., Sodroski J.;
"Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.";
J. Virol. 79:12132-12147(2005).
[10]
REVIEW.
DOI=10.1016/S0005-2736(03)00161-5; PubMed=12873764 [NCBI, ExPASy, EBI, Israel, Japan]
Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., Blumenthal R.;
"The HIV Env-mediated fusion reaction.";
Biochim. Biophys. Acta 1614:36-50(2003).
[11]
REVIEW.
DOI=10.1038/sj.cdd.4401584; PubMed=15719026 [NCBI, ExPASy, EBI, Israel, Japan]
Perfettini J.-L., Castedo M., Roumier T., Andreau K., Nardacci R., Piacentini M., Kroemer G.;
"Mechanisms of apoptosis induction by the HIV-1 envelope.";
Cell Death Differ. 12:916-923(2005).
[12]
REVIEW.
DOI=10.1089/aid.2005.21.171; PubMed=15725757 [NCBI, ExPASy, EBI, Israel, Japan]
Hartley O., Klasse P.J., Sattentau Q.J., Moore J.P.;
"V3: HIV's switch-hitter.";
AIDS Res. Hum. Retroviruses 21:171-189(2005).
[13]
REVIEW.
DOI=10.2165/00003495-200565130-00002; PubMed=16114975 [NCBI, ExPASy, EBI, Israel, Japan]
Reeves J.D., Piefer A.J.;
"Emerging drug targets for antiretroviral therapy.";
Drugs 65:1747-1766(2005).
[14]
REVIEW.
DOI=10.1038/sj.emboj.7600947; PubMed=16437164 [NCBI, ExPASy, EBI, Israel, Japan]
Lusso P.;
"HIV and the chemokine system: 10 years later.";
EMBO J. 25:447-456(2006).
[15]
X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 83-492 IN COMPLEX WITH HUMAN CD4.
DOI=10.1038/31405; PubMed=9641677 [NCBI, ExPASy, EBI, Israel, Japan]
Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A.;
"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.";
Nature 393:648-659(1998).
Comments
  • FUNCTION: The surface protein gp120 (SU) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. This peculiar 2 stage receptor-interaction strategy allows gp120 to maintain the highly conserved coreceptor-binding site in a cryptic conformation, protected from neutralizing antibodies. Since CD4 also displays a binding site for the disulfide-isomerase P4HB/PDI, a P4HB/PDI-CD4-CXCR4-gp120 complex may form. In that complex, P4HB/PDI could reach and reduce gp120 disulfide bonds, causing major conformational changes in gp120. TXN, another PDI family member could also be involved in disulfide rearrangements in Env during fusion. These changes are transmitted to the transmembrane protein gp41 and are thought to activate its fusogenic potential by unmasking its fusion peptide. Fusion occurs at the host cell plasma membrane (By similarity).
  • FUNCTION: The transmembrane protein gp41 (TM) acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
  • FUNCTION: The surface protein gp120 is a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they take up antigen, process it, and present it to T cells following migration to lymphoid organs. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T cells. Virion capture also seems to lead to MHC-II-restricted viral antigen presentation, and probably to the activation of HIV-specific CD4+ cells.
  • FUNCTION: The envelope glyprotein gp160 precursor down-modulates cell surface CD4 antigen by interacting with it in the endoplasmic reticulum and blocking its transport to the cell surface (By similarity).
  • FUNCTION: Seems to contribute to T-cell depletion during HIV-1 infection. The envelope glycoproteins expressed on the surface of infected cells induce apoptosis through an interaction with uninfected cells expressing the receptor (CD4) and the coreceptors CXCR4 or CCR5. This type of bystander killing may be obtained by at least three distinct mechanisms. First, the interaction between the 2 cells can induce cellular fusion followed by nuclear fusion within the syncytium. Syncytia are condemned to die from apoptosis. Second, the 2 interacting cells may not fuse entirely and simply exchange plasma membrane lipids, after a sort of hemifusion process, followed by rapid death. Third, it is possible that virus-infected cells, on the point of undergoing apoptosis, fuse with CD4-expressing cells, in which case apoptosis is rapidly transmitted from one cell to the other and thus occurs in a sort of contagious fashion.
  • FUNCTION: Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves.
  • SUBUNIT: The mature envelope protein (Env) consists of a homotrimer of noncovalently associated gp120-gp41 heterodimers. The resulting complex protrudes from the virus surface as a spike. There seems to be as few as 10 spikes on the average virion. Surface protein gp120 interacts with human CD4, CCR5 and CXCR4, to form a P4HB/PDI-CD4-CXCR4-gp120 complex (By similarity). Gp120 also interacts with the C-type lectins CD209/DC-SIGN and CLEC4M/DC-SIGNR (collectively referred to as DC-SIGN(R)). Gp120 and gp41 interact with GalCer.
  • SUBCELLULAR LOCATION: Transmembrane protein: Virion membrane; Single-pass type I membrane protein. Cell membrane; Single-pass type I membrane protein. Note=It is probably concentrated at the site of budding and incorporated into the virions possibly by contacts between the cytoplasmic tail of Env and the N-terminus of Gag.
  • SUBCELLULAR LOCATION: Surface protein: Virion membrane; Peripheral membrane protein. Cell membrane; Peripheral membrane protein. Note=The surface protein is not anchored to the viral envelope, but associates with the extravirion surface through its binding to TM. It is probably concentrated at the site of budding and incorporated into the virions possibly by contacts between the cytoplasmic tail of Env and the N-terminus of Gag.
  • DOMAIN: The YXXL motif is involved in determining the exact site of viral release at the surface of infected mononuclear cells and promotes endocytosis.
  • DOMAIN: The 17 amino acids long immunosuppressive region is present in many retroviral envelope proteins. Synthetic peptides derived from this relatively conserved sequence inhibit immune function in vitro and in vivo (By similarity).
  • DOMAIN: Some of the most genetically diverse regions of the viral genome are present in Env. They are called variable regions 1 through 5 (V1 through V5). Coreceptor usage of gp120 is determined mainly by the primary structure of the third variable region (V3) in the outer domain of gp120. The sequence of V3 determines which coreceptor, CCR5 and/or CXCR4 (corresponding to R5/macrophage, X4/T cell and R5X4/T cell and macrophage tropism), is used to trigger the fusion potential of the Env complex, and hence which cells the virus can infect. Binding to CCR5 involves a region adjacent in addition to V3.
  • PTM: Specific enzymatic cleavages in vivo yield mature proteins. Envelope glycoproteins are synthesized as a inactive precursor that is heavily N-glycosylated and processed likely by host cell furin in the Golgi to yield the mature SU and TM proteins. The cleavage site between SU and TM requires the minimal sequence [KR]-X-[KR]-R. About 2 of the 9 disulfide bonds of gp41 are reduced by P4HB/PDI, following binding to CD4 receptor (By similarity).
  • PTM: Palmitoylation of the transmembrane protein and of Env polyprotein (prior to its proteolytic cleavage) is essential for their association with host cell membrane lipid rafts. Palmitoylation is therefore required for envelope trafficking to classical lipid rafts, but not for viral replication (By similarity).
  • MISCELLANEOUS: Inhibitors targeting HIV-1 viral envelope proteins are used as antiretroviral drugs. Attachment of virions to the cell surface via nonspecific interactions and CD4 binding can be blocked by inhibitors that include cyanovirin-N, cyclotriazadisulfonamide analogs, PRO 2000, TNX 355 and PRO 542. In addition, BMS 806 can block CD4-induced conformational changes. Env interactions with the coreceptor molecules can be targeted by CCR5 antagonists including SCH-D, maraviroc (UK 427857) and aplaviroc (GW 873140), and the CXCR4 antagonist AMD 070. Fusion of viral and cellular membranes can be inhibited by peptides such as enfuvirtide and tifuvirtide (T 1249). Resistance to inhibitors associated with mutations in Env are observed. Most of the time, single mutations confer only a modest reduction in drug susceptibility. Combination of several mutations is usually required to develop a high-level drug resistance.
  • MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M (for Major), O (for Outlier), and N (for New, or Non-M, Non-O). The vast majority of strains found worldwide belong to the group M. Group O seems to be endemic to and largely confined to Cameroon and neighboring countries in West Central Africa, where these viruses represent a small minority of HIV-1 strains. The group N is represented by a limited number of isolates from Cameroonian persons. The group M is further subdivided in 9 clades or subtypes (A to D, F to H, J and K).
  • WEB RESOURCE: Name=resdb; Note=HIV resistance database; URL="http://resdb.lanl.gov/Resist_DB/";.
  • WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=Env entry; URL="http://www.bioafrica.net/proteomics/ENVprot.html";.
  • WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=gp120 entry; URL="http://www.bioafrica.net/proteomics/ENV-GP120prot.html";.
  • WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=gp41 entry; URL="http://www.bioafrica.net/proteomics/ENV-GP41prot.html";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
K03455; AAB50262.1; -; Genomic_RNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF038399; AAB99976.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF033819; AAC82596.1; -; Genomic_RNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
RefSeq NP_057856.1; -.
3D structure databases
PDB
1AIK; X-ray; 2.00 A; C=628-661, N=546-581.[ExPASy / RCSB / EBI]
1DF4; X-ray; 1.45 A; A=546-593.[ExPASy / RCSB / EBI]
1DF5; X-ray; 2.70 A; A=546-593.[ExPASy / RCSB / EBI]
1DLB; X-ray; 2.00 A; A=546-593.[ExPASy / RCSB / EBI]
1G9M; X-ray; 2.20 A; G=156-492.[ExPASy / RCSB / EBI]
1GC1; X-ray; 2.50 A; G=195-492.[ExPASy / RCSB / EBI]
1GZL; X-ray; 1.80 A; A/B=565-581, C/D=628-639.[ExPASy / RCSB / EBI]
1K33; X-ray; 1.75 A; A=546-593.[ExPASy / RCSB / EBI]
1K34; X-ray; 1.88 A; A=546-593.[ExPASy / RCSB / EBI]
1OPN; Model; -; G=156-492.[ExPASy / RCSB / EBI]
1OPT; Model; -; G=156-492.[ExPASy / RCSB / EBI]
1OPW; Model; -; G=156-492.[ExPASy / RCSB / EBI]
1RZJ; X-ray; 2.20 A; G=156-492.[ExPASy / RCSB / EBI]
2CMR; X-ray; 2.00 A; A=606-804.[ExPASy / RCSB / EBI]
2PV6; NMR; -; A=662-683.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1AIK; -.
1DF4; -.
1DF5; -.
1DLB; -.
1G9M; -.
1GC1; -.
1GZL; -.
1K33; -.
1K34; -.
1OPN; -.
1OPT; -.
1OPW; -.
1RZJ; -.
2CMR; -.
2PV6; -.
SMR P04578; 540-626.
ModBase P04578.
Enzyme and pathway databases
Reactome REACT_6185; HIV Infection.
Ontologies
GO
GO:0019059; Biological process: initiation of viral infection (inferred from experiment from Reactome).
QuickGo view.
Family and domain databases
InterPro IPR000328; Env_GP41.
IPR000777; GP120.
Graphical view of domain structure.
Gene3D G3DSA:2.170.40.20; GP120; 1.
Pfam PF00516; GP120; 1.
PF00517; GP41; 1.
Pfam graphical view of domain structure.
BLOCKS P04578.
ProtoNet P04578.
Genome annotation databases
GeneID 155971; -.
Other
LinkHub P04578; -.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; AIDS; Apoptosis; Cell membrane; Cleavage on pair of basic residues; Coiled coil; Envelope protein; Fusion protein; Glycoprotein; Host-virus interaction; Lipoprotein; Membrane; Palmitate; Signal; Transmembrane; Viral immunoevasion; Virion.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
SIGNAL   1    32  32     By similarity. 
CHAIN   33   856  824     Envelope glycoprotein gp160. PRO_0000239240
CHAIN   33   511  479     Surface protein (By similarity). PRO_0000038427
CHAIN   512   856  345     Transmembrane protein (By similarity). PRO_0000038428
TOPO_DOM   33   684  652     Extracellular (Potential). 
TRANSMEM   685   705  21     Potential. 
TOPO_DOM   706   856  151     Cytoplasmic (Potential). 
REGION   131   156  26     V1. 
REGION   157   196  40     V2. 
REGION   296   330  35     V3. 
REGION   385   418  34     V4. 
REGION   461   471  11     V5. 
REGION   512   532  21     Fusion peptide (Potential). 
REGION   576   592  17     Immunosuppression. 
REGION   662   667  6     Involved in GalCer binding (By similarity). 
COILED   542   592  51     Potential. 
COILED   633   667  35     Potential. 
MOTIF   712   715  4     YXXL motif; contains endocytosis signal. 
SITE   511   512  2     Cleavage; by host furin (By similarity). 
LIPID   764   764        S-palmitoyl cysteine; by host. 
LIPID   837   837        S-palmitoyl cysteine; by host. 
CARBOHYD   88    88        N-linked (GlcNAc...) (Potential). 
CARBOHYD   136   136        N-linked (GlcNAc...) (Potential). 
CARBOHYD   141   141        N-linked (GlcNAc...) (Potential). 
CARBOHYD   156   156        N-linked (GlcNAc...) (Potential). 
CARBOHYD   160   160        N-linked (GlcNAc...) (Potential). 
CARBOHYD   186   186        N-linked (GlcNAc...) (Potential). 
CARBOHYD   197   197        N-linked (GlcNAc...) (Potential). 
CARBOHYD   230   230        N-linked (GlcNAc...) (Potential). 
CARBOHYD   234   234        N-linked (GlcNAc...) (Potential). 
CARBOHYD   241   241        N-linked (GlcNAc...) (Potential). 
CARBOHYD   262   262        N-linked (GlcNAc...) (Potential). 
CARBOHYD   276   276        N-linked (GlcNAc...) (Potential). 
CARBOHYD   289   289        N-linked (GlcNAc...) (Potential). 
CARBOHYD   295   295        N-linked (GlcNAc...) (Potential). 
CARBOHYD   301   301        N-linked (GlcNAc...) (Potential). 
CARBOHYD   332   332        N-linked (GlcNAc...) (Potential). 
CARBOHYD   339   339        N-linked (GlcNAc...) (Potential). 
CARBOHYD   356   356        N-linked (GlcNAc...) (Potential). 
CARBOHYD   386   386        N-linked (GlcNAc...) (Potential). 
CARBOHYD   392   392        N-linked (GlcNAc...) (Potential). 
CARBOHYD   397   397        N-linked (GlcNAc...) (Potential). 
CARBOHYD   406   406        N-linked (GlcNAc...) (Potential). 
CARBOHYD   448   448        N-linked (GlcNAc...) (Potential). 
CARBOHYD   463   463        N-linked (GlcNAc...) (Potential). 
CARBOHYD   611   611        N-linked (GlcNAc...) (Potential). 
CARBOHYD   616   616        N-linked (GlcNAc...) (Potential). 
CARBOHYD   624   624        N-linked (GlcNAc...) (Potential). 
CARBOHYD   637   637        N-linked (GlcNAc...) (Potential). 
CARBOHYD   674   674        N-linked (GlcNAc...) (Potential). 
DISULFID   54    74        By similarity. 
DISULFID   119   205        By similarity. 
DISULFID   126   196        By similarity. 
DISULFID   131   157        By similarity. 
DISULFID   218   247        By similarity. 
DISULFID   228   239        By similarity. 
DISULFID   296   331        By similarity. 
DISULFID   378   445        By similarity. 
DISULFID   385   418        By similarity. 
MUTAGEN   764   764        C->S: Complete loss of palmitoylation, decreased association with host cell membrane lipid rafts, decreased incorporation onto virions and severe reduction of infectivity; when associated with S-837. 
MUTAGEN   837   837        C->S: Complete loss of palmitoylation, decreased association with host cell membrane lipid rafts, decreased incorporation onto virions and severe reduction of infectivity; when associated with S-764. 
HELIX   163   177  15      
STRAND   183   187  5      
STRAND   192   195  4      
STRAND   199   201  3      
STRAND   223   228  6      
STRAND   235   247  13      
STRAND   256   258  3      
STRAND   260   262  3      
STRAND   267   269  3      
STRAND   271   273  3      
STRAND   284   297  14      
TURN   327   329  3      
STRAND   330   334  5      
HELIX   335   352  18      
STRAND   359   361  3      
HELIX   369   372  4      
STRAND   374